ArticlePloS one2012
Fumaric acid production in Saccharomyces cerevisiae by in silico aided metabolic engineering.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 66 citations in OpenAlex.
- Fumarate and fumarate hydratase: an immunometabolite regulator of inflammation and diseases.Frontiers in immunology · 2026Review
- Advancing yeast metabolism for a sustainable single carbon bioeconomy.FEMS yeast research · 2025Review
- Fungal carboxylate transporters: recent manipulations and applications.Applied microbiology and biotechnology · 2023Review
- Metabolic Engineering and Adaptive Evolution for Efficient Production of l-Lactic Acid in Saccharomyces cerevisiae.Microbiology spectrum · 2022Article
- Article
- Metabolic flux sampling predicts strain-dependent differences related to aroma production among commercial wine yeasts.Microbial cell factories · 2021Article
- Model-guided development of an evolutionarily stable yeast chassis.Molecular systems biology · 2021Article
- Fumaric acid protect the cadmium-induced hepatotoxicity in rats: owing to its antioxidant, anti-inflammatory action and aid in recast the liver function.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- Membrane transporters in the bioproduction of organic acids: state of the art and future perspectives for industrial applications.FEMS microbiology letters · 2020Review
- Metabolic fluxes-oriented control of bioreactors: a novel approach to tune micro-aeration and substrate feeding in fermentations.Microbial cell factories · 2019Article
- Genome-Scale Metabolic Modeling from Yeast to Human Cell Models of Complex Diseases: Latest Advances and Challenges.Methods in molecular biology (Clifton, N.J.) · 2019Article
- Reconstruction of a genome-scale metabolic model for Actinobacillus succinogenes 130Z.BMC systems biology · 2018Article
- Genome-scale modeling of yeast: chronology, applications and critical perspectives.FEMS yeast research · 2017Review
- Comparative proteomics ofPeerJ · 2017Article
- Fumarate Production by Torulopsis glabrata: Engineering Heterologous Fumarase Expression and Improving Acid Tolerance.PloS one · 2016Article
- Sequence- and Structure-Based Functional Annotation and Assessment of Metabolic Transporters in Aspergillus oryzae: A Representative Case Study.BioMed research international · 2016Article
- Metabolic engineering of carbon and redox flow in the production of small organic acids.Journal of industrial microbiology & biotechnology · 2015Review
- Enhancement of acetoin production in Candida glabrata by in silico-aided metabolic engineering.Microbial cell factories · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fumaric acid (FA) is a promising biomass-derived building-block chemical. Bio-based FA production from renewable feedstock is a promising and sustainable alternative to petroleum-based chemical synthesis. Here we report on FA production by direct fermentation using metabolically engineered Saccharomyces cerevisiae with the aid of in silico analysis of a genome-scale metabolic model. First, FUM1 was selected as the target gene on the basis of extensive literature mining. Flux balance analysis (FBA) revealed that FUM1 deletion can lead to FA production and slightly lower growth of S. cerevisiae. The engineered S. cerevisiae strain obtained by deleting FUM1 can produce FA up to a concentration of 610±31 mg L(-1) without any apparent change in growth in fed-batch culture. FT-IR and (1)H and (13)C NMR spectra confirmed that FA was synthesized by the engineered S. cerevisiae strain. FBA identified pyruvate carboxylase as one of the factors limiting higher FA production. When the RoPYC gene was introduced, S. cerevisiae produced 1134±48 mg L(-1) FA. Furthermore, the final engineered S. cerevisiae strain was able to produce 1675±52 mg L(-1) FA in batch culture when the SFC1 gene encoding a succinate-fumarate transporter was introduced. These results demonstrate that the model shows great predictive capability for metabolic engineering. Moreover, FA production in S. cerevisiae can be efficiently developed with the aid of in silico metabolic engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.